PGY2 Psychiatric Pharmacy

Description and Purpose

This PGY2 Psychiatric Pharmacy Residency Program offers a variety of learning experiences in psychiatric pharmacy at two practice sites, McLean Hospital (MCL) and Massachusetts General Hospital (MGH). The mission of this residency program is to educate and refine the pharmacy resident’s skills in clinical pharmacy practice and patient care. This will be achieved through various learning experiences such as providing patient care in a variety of psychiatric settings, precepting pharmacy students and interns, clinical research, education of other disciplines, and committee involvement. Our goal is to help pharmacy residents develop their clinical skills to practice autonomously as an integral member of the healthcare team in a professional, ethical, and competent manner.

The purpose of this PGY2 residency program is to provide residents the opportunity to build upon their Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency experience to become clinical pharmacists in a specialized area of practice. PGY2 training allows pharmacy residents to practice independently by conceptualizing and integrating their previously accumulated experience and knowledge and incorporating them both into direct patient care. Upon completion of this program, pharmacy residents will be well-prepared for clinical pharmacy practice and patient care, academia, or other specialized positions, in addition to board certification in psychiatric pharmacy.

We currently offer two positions for the PGY2 Psychiatric Pharmacy Residency Program.

About McLean Hospital

Founded in 1811, McLean Hospital is a leader in psychiatric care, research, and education and is the largest psychiatric teaching hospital of Harvard Medical School. Our staff, faculty, volunteers, and supporters are dedicated to improving the lives of individuals and families affected by mental illness. McLean offers high-quality mental health treatment for individuals of all ages experiencing a wide array of symptoms and diagnoses. Our programs are ideal for those who are having trouble identifying mental health diagnoses or struggling with managing symptoms. We specialize in hard-to-treat cases and in working with individuals who have been in treatment but are not achieving their desired treatment goals.

Consistently ranked as a top hospital in U.S. News & World Report’s annual Best Hospitals survey, the staff at McLean recognize the importance of partnering with our patients and their families to successfully manage the conditions we treat. McLean clinicians and staff work together with patients to create customized treatment plans that focus on the individual’s goals, helping them learn the skills necessary to live successful, meaningful lives.

Learn more about McLean Hospital »

Program Goals

• In collaboration with the healthcare team, provide comprehensive medication management to patients with psychiatric and neurologic disorders following a consistent patient care process
• Ensure continuity of care during transitions between care settings for patients with psychiatric and neurologic disorders
• Demonstrate ability to manage formulary and medication-use processes for patients with psychiatric and neurologic disorders, as applicable to the organization
• Demonstrate ability to conduct a quality improvement or research project
• Demonstrate leadership skills for successful self-development in the provision of care for patients with psychiatric and neurologic disorders
• Demonstrate understanding of management in the provision of care for psychiatric patients
• Provide effective medication and practice-related education associated with the care of patients with psychiatric and neurologic disorders, caregivers, health professionals, students, and the public (individuals and groups)
• Employ appropriate preceptor roles when engaged in teaching students, pharmacy technicians, or fellow healthcare professionals related to care of patients with psychiatric and neurologic disorders
• Demonstrate understanding of the management of psychiatric emergencies

Learning Experiences

Required Learning Experiences (7):

• Orientation (4 weeks)
• Adult inpatient psychiatry (4 weeks)
• Adult inpatient medical psychiatry (4 weeks)
• Child and adolescent psychiatry OR geriatric psychiatry (4 weeks)
• Inpatient substance use disorders (4 weeks)
• Mood and affective disorders (4 weeks)
• Psychotic disorders (4 weeks)

Required Longitudinal Learning Experiences (4):

• Longitudinal outpatient psychiatry (≥26 weeks)
• Longitudinal education and preceptor development (52 weeks)
• Longitudinal pharmacy practice experience (52 weeks)
  • Two shifts per month (evening or weekend)
  • One holiday shift per academic year
• Longitudinal research project (52 weeks)

Elective Learning Experiences (6):

• Electroconvulsive therapy and neurotherapeutics (2 weeks)
• Child and adolescent psychiatry OR geriatric psychiatry (4 weeks)
• Dissociative disorders and trauma (4 weeks)
• Geriatric neurocognitive disorders (4 weeks)
• Neurology (4 weeks)
• Pharmacy administration (4 weeks)
• Treatment resistant psychosis (4 weeks)

Preceptors

Lauren Stummer, PharmD, BCPP

PGY2 Psychiatric Pharmacy Residency Program Director

Education: Doctor of Pharmacy, Wegmans School of Pharmacy at St. John Fisher College (2016)

Training: PGY1, RWJBarnabas Behavioral Health (2017); PGY2 Neuropsychiatry, The Ernest Mario School of Pharmacy at Rutgers (2018)

Practice Site: McLean Hospital Comprehensive Adult Psychiatry Unit

Involvement: American Association of Psychiatric Pharmacists; American Society of Health-System Pharmacists; Massachusetts General Hospital Pharmacy Education Committee; Massachusetts General Hospital Residency Executive Committee; Massachusetts Society of Health-System Pharmacists Programming Committee (Annual Meeting Subcommittee); McLean Hospital Pharmacy Residency Advisory Committee

Hometown: Camillus, NY

Jen Corapi, PharmD, BCPP

Education: Doctor of Pharmacy, Northeastern University (2017)

Training: PGY1, San Francisco VA Medical Center (2018); PGY2 Psychiatry, Zuckerberg San Francisco General Hospital (2019)

Practice Site(s): Massachusetts General Hospital Adult Inpatient Psychiatry Unit; Massachusetts General Hospital Addiction Consult Team; Massachusetts General Hospital Outpatient Psychiatry Clinic

Involvement: American Association of Psychiatric Pharmacists; Massachusetts General Hospital Pharmacy Credentialing Committee; Massachusetts General Hospital Pharmacy Event Planning Committee; McLean Hospital Pharmacy Residency Advisory Committee

Hometown: Syracuse, NY

Christie Costello, PharmD, BCPS, BCPP

Education: Doctor of Pharmacy, University of Connecticut (2020)

Training: PGY1, Bridgeport Hospital Yale New Haven Health (2021); PGY2 Psychiatry, Medical University of South Carolina (2022)

Practice Site: McLean Hospital Mood Disorders Unit

Involvement: American Association of Psychiatric Pharmacists Student Committee

Hometown: Trumbull, CT

Bridgette Gleisner, PharmD, BCPP

Education: Doctor of Pharmacy, University of Maryland School of Pharmacy (2019)

Training: PGY1, Conemaugh Memorial Medical Center (2020); PGY2 Psychiatry, Fulton State Hospital (2021)

Practice Site: McLean Hospital Psychotic Disorders Unit

Involvement: American Association of Psychiatric Pharmacists; Mass General Brigham Medication Warnings Clinical Consensus Group

Hometown: Graysville, PA

Riley Johnson, PharmD, FAES

Education: Doctor of Pharmacy, University of Wyoming (2020)

Training: PGY1, Wyoming Medical Center (2021); PGY2 Neurology, VA Greater Los Angeles Healthcare System (2022)

Practice Site: Massachusetts General Hospital Neurology Unit

Involvement: American Epilepsy Society; American Pharmacists Association

Hometown: Greeley, CO

Andrew Karas, PharmD, BCPP

Education: Doctor of Pharmacy, University of Georgia College of Pharmacy (2017)

Training: PGY1, Mount Sinai Beth Israel Hospital (2018); PGY2 Psychiatry, Nova Southeastern University College of Pharmacy (2019)

Practice Site: McLean Hospital Dissociative Disorders and Trauma Unit

Involvement: American Association of Psychiatric Pharmacists; McLean Hospital Pharmacy Residency Advisory Committee

Hometown: Peachtree City, GA

Zoe Karavolis, PharmD, BCPP

Education: Doctor of Pharmacy, Northeastern University (2020)

Training: PGY1, UPMC Presbyterian (2021); PGY2 Psychiatry, UPMC Western Psychiatric Hospital (2022)

Practice Site: McLean Hospital Alcohol, Drug, and Addiction Treatment Unit

Involvement: American Association of Psychiatric Pharmacists Student Committee; Massachusetts Harm Reduction Program; Mass General Brigham Substance Use Steering Committee

Hometown: Rehoboth, MA

Michael J. Mandarino, PharmD, BCPS, BCPP

Education: Doctor of Pharmacy, Albany College of Pharmacy and Health Sciences (2019)

Training: PGY1, Montefiore Nyack Hospital (2020); PGY2 Psychiatry, RWJBarnabas Behavioral Health (2021)

Practice Site(s): McLean Hospital Older Adult Psychiatry Unit; McLean Hospital Cognitive Neuropsychiatry Unit; McLean Hospital Neuropsychiatry and Behavioral Neurology Consult Team

Involvement: American Association of Psychiatric Pharmacists; McLean Hospital Division of Geriatric Psychiatry; McLean Hospital Falls Committee; McLean Hospital Infection Control Committee; McLean Hospital Pharmacy Residency Advisory Committee

Hometown: Warwick, NY

Brianne Mosley, PharmD, BCPS, BCPP

Education: Doctor of Pharmacy, Ohio Northern University Raabe College of Pharmacy (2019)

Training: PGY1, The Johns Hopkins Hospital (2020); PGY2 Psychiatry, Medical University of South Carolina (2021)

Practice Site: McLean Hospital Treatment Resistant Psychosis and Community Reintegration Unit

Involvement: American Association of Psychiatric Pharmacists Program Committee; Massachusetts Society of Health-System Pharmacists Programming Committee (Annual Meeting Subcommittee, Honors and Awards Subcommittee); Massachusetts Society of Health-System Pharmacists Student Committee

Hometown: Bremen, Ohio

Kelsey Shadick, PharmD

Education: Doctor of Pharmacy, Western New England University College of Pharmacy and Health Sciences (2020)

Training: PGY1, Lawrence + Memorial Hospital Yale New Haven Health (2021); PGY2 Psychiatry, VA Connecticut Healthcare System (2022)

Practice Site(s): McLean Southeast and McLean Southeast at Oak Street

Involvement: American Association of Psychiatric Pharmacists

Hometown: Albany, NY

Joshua Spencer, PharmD

Education: Doctor of Pharmacy, University of Kentucky College of Pharmacy (2020)

Training: PGY1, James H. Quillen VA Medical Center (2021); PGY2 Psychiatry, VA Boston Healthcare System (2022)

Practice Site: Massachusetts General Hospital Adult Inpatient Psychiatry Unit

Involvement: American Association of Psychiatric Pharmacists

Hometown: Taylorsville, KY

Andrew Webb, PharmD, BCCCP

Education: Doctor of Pharmacy, University of Rhode Island (2019)

Training: PGY1, Mayo Clinic (2020); PGY2 Critical Care, Oregon Health & Science University (2021)

Practice Site: Massachusetts General Hospital Neurocritical Care Unit

Involvement: American College of Clinical Pharmacy; Neurocritical Care Society; Society of Critical Care Medicine

Hometown: Wyoming, RI

Benefits

• Competitive stipend
• Health insurance options
• Vacation days, paid holidays, and sick time
• Professional materials (laptop, office space, drug information resources, etc.)
• Travel reimbursement for approved conferences
• Professional memberships for AAPP, ASHP, and MSHP

How to Apply

To be eligible to apply for the PGY2 Psychiatric Pharmacy Residency Program, applicants must be graduates of an ACPE-accredited school of pharmacy with a Doctor of Pharmacy (PharmD) degree and have completed or are in the process of completing an ASHP-accredited PGY1 residency program. Applications must be submitted via PhORCAS and include the following to be complete:

• Formal letter of intent
• Curriculum Vitae
• Official pharmacy school transcripts and undergraduate transcripts (if applicable)
• Three standardized references completed through PhORCAS

The deadline for receipt of a completed PhORCAS application is January 7^th, 2024. Upon completion of applications review, qualified candidates will be contacted regarding interviews. The PGY2 Psychiatric Pharmacy Residency Program participates in the ASHP Resident Matching Program.

International applicants are welcome to apply if the applicant is eligible to work in the United States from July 2024 - June 2025 and will be considered based on the merits of the candidate's application. McLean Hospital and Massachusetts General Hospital Departments of Pharmacy are unable to sponsor H1B Visas.

This residency program welcomes and encourages diverse applications. It is the policy of Mass General Brigham to affirmatively provide equal opportunity to all qualified applicants for employment and existing employees without regard to race, religion, color, national origin, sex, age, ancestry, protected veteran status, disability, sexual orientation, gender identity or expression, pregnancy or a condition related to pregnancy including, but not limited to, lactation or the need to express breast milk for a nursing child, or any other basis that would be in violation of any applicable law or regulation.

Contact Information

Lauren Stummer, PharmD, BCPP
Clinical Operational Pharmacist
Director, PGY2 Psychiatric Pharmacy Residency Program
lstummer@partners.org